Lipocine Inc. $(LPCN)$, a biopharmaceutical company, has announced an upcoming virtual research and development investor event scheduled for July 9, 2025. The event will discuss LPCN 1154 (BRLIZIO™), a treatment for postpartum depression $(PPD)$. The presentation will feature Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, Northwell Health, New York, along with company management, who will discuss the current treatment landscape and unmet needs in PPD. Lipocine's LPCN 1154 is noted for its potential as the first line option for rapid symptom relief in women with PPD, with a 48-hour treatment duration in an outpatient setting through an oral form. The event will include updates on clinical, regulatory, and development aspects, particularly focusing on the recently initiated Phase 3 registrational study, which is expected to yield results in Q2-2026. A live Q&A session will follow the presentations.